Dr. Reddy's Laboratories

Pleased to share that we have won the 'Masters of Risk - Healthcare and Pharma' category award at the India Risk Management Awards. India Risk Management Awards, presented by CNBC-TV18 and ICICI Lombard, recognises work done by organisations in the field of risk management. Our team was present in Mumbai to receive the award. This achievement comes as a recognition of our innovative and strategic approach to risk management even in times of uncertainty. We continue to work towards enhancing trust with our stakeholders by being vigilant and preparing ahead. #WeAreDrReddys #GoodHealthCantWait #RiskManagementAwards

40 years of serving patients – for four decades, we have stood for advancing healthcare. ‘Good Health Can’t Wait’ has become a movement and call to action for all of us, encompassing people, planet and patients. Amidst the evolution, what has remained unchanged is our endeavour to keep access, affordability, innovation at the heart of everything we do. By the end of FY’24, we had served over 700 million patients and continue our endeavour to reach over 1.5 billion patients globally by 2030. Our Integrated Annual Report highlights our 40-year journey, messages from the leaders, showcases how we create value for stakeholders, progress on our ESG goals, management commentary on business outlook, and financial statements. As the pharmaceutical industry evolves, we will continue to work on strengthening our core businesses further and continue to invest in building the future of healthcare. To read our Annual Report, please visit: https://shorturl.at/pzi1N #GoodHealthCantWait #WeAreDrReddys #IntegratedReport

Aurigene is excited to announce a strategic partnership with Edity Therapeutics which aims to accelerate innovation in drug discovery! Edity has developed the first-ever 𝐢𝐦𝐦𝐮𝐧𝐞 𝐜𝐞𝐥𝐥 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦, enabling the selective delivery of intracellular proteins to diseased tissues.  Aurigene will provide 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 to support with clinical development. Aurigene has 20+ years of expertise in supporting 𝐠𝐥𝐨𝐛𝐚𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 with accelerated development timelines and cost-effective manufacturing for 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐚𝐧𝐝 𝐬𝐦𝐚𝐥𝐥 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬. Akhil Ravi, CEO - Aurigene, said, "We are excited about the collaboration and look forward to working with Edity in building novel technologies. Edity’s cellular reprogramming technology to deliver therapeutic payloads, specifically to target cells, adds a new mechanism to CAR-T based cell therapeutics with the potential to significantly increase the efficacy." Michal Golan Mashiach, Ph.D, CEO - Edity, said “We are thrilled to be working with Aurigene's world-class team. Their experience and breadth of technology offerings will help Edity to advance our pipeline and help patients with severe diseases. This collaboration will support our growth as we seek to create best-in-class medicines.” Roger Lias, Global Commercial Head – Biologics, Aurigene, added, “We are delighted to add Edity to the growing list of global companies recognizing Aurigene as a valued partner in the biologics and advanced therapies space. Our true end-to-end service offering from discovery through large-scale CGMP manufacture allows us to efficiently deliver speed, unwavering quality and economically viable solutions to our customers as they bring much-needed therapeutics to patients.” #strategicpartnerships #collaboration #celldelivery #drugdiscovery #therapeutics You can read the full story here! https://lnkd.in/gaZA9qCd

Pleased to announce that are featured in the Time Magazine and Statista list of Global 500 Most Sustainable Companies 2024. Over 20 data points were collected on Environment, Social and Governance parameters on over 5,200 companies globally to arrive at the final 500 based on commitments and ratings, reporting transparency, and stewardship in diverse areas such as emissions, renewable energy, water usage, gender parity, women in leadership, work safety, etc. To read more, click on: https://lnkd.in/dAxy8_Ag Through our ESG goals, we endeavour to contribute to the well-being of patients, people, planet. To read more about our ESG goals, please visit: http://bit.ly/3ZMMWRM #DrReddysXSustainability #ESG #Sustainability #GoodHealthCantWait #WeAreDrReddys

Our manufacturing facilities have absorbed 250 apprentices into their front-line workforce through a meticulously crafted apprenticeship program over 15 months. The programme is designed to tap into a pool of diverse talent with qualifications spanning from Diploma to M. Pharm, aligning them with the specific needs of different business units. The most significant impact of this programme lies in its role as a talent pipeline builder. This provides a great model to address talent availability in niche skills and create a steady stream of skilled individuals ready to take on the challenges of tomorrow. At present, 680 apprentices are contributing across 16 units. We wish all our apprentices the best in this journey of contributing to our purpose of 'Good Health Can't Wait'.   #WeAreDrReddys #HumansOfDrReddys #GoodHealthCantWait  

Sathya Prathipati, Senior Partner at McKinsey & Company, moderated an illustrious panel of pharma industry luminaries at the Indian Pharmaceutical Alliance's 9th Global Pharmaceutical Quality Summit 2024. Leading the discussions were- MD & CEO of Cipla Umang Vohra; Co-chair of Dr Reddy’s Laboratories Prasad G V; Managing Director of Lupin Nilesh Gupta; Founder and CMD of Sun Pharmaceuticals Dilip Shanghvi, and Zydus Lifesciences Chairman, Pankaj Patel. In a lively discussion, panelists discussed pivotal strategies for the #pharmaceutical industry to advance significantly in the coming decade. Watch this space for more updates. #GPQS24 #GPQS2024 #pharma

Our team in Princeton, USA, has been observing #30DaysOfPride in solidarity with the global agenda of diversity, equity and inclusion (DEI). Our colleagues discussed the history of PRIDE, gender and allyship. They also provided LGBTQ+ resources to further self-education efforts and support. Pride-themed cupcakes, fruits and snacks were provided by local minority and women-owned businesses added to the occasion. Our DEI journey may be young but our colleagues across geographies continue to work towards being allies, celebrating diversity and embracing the unique contributions of every individual, beyond a single observance day or month. Through our ESG goals, we carry on our efforts to empower our colleagues and the community around us to build a more inclusive and welcoming environment.   #WeAreDrReddys #DrReddysXInclusivity #DEI #30DaysofPride #DrReddysXSustainability #GoodHealthCantWait

In a recent CEO round table organized by CII Telangana, our CEO, Akhil Ravi, along with other eminent industry leaders, shared their viewpoints on the 𝐠𝐫𝐨𝐰𝐭𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐩𝐡𝐚𝐫𝐦𝐚 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐬𝐞𝐜𝐭𝐨𝐫. The panel also discussed the regulatory challenges and how Indian pharma services companies can look at new opportunities in the emerging geopolitical environment, specifically the recent moves around the 𝐁𝐢𝐨𝐬𝐞𝐜𝐮𝐫𝐞 𝐀𝐜𝐭 𝐛𝐲 𝐭𝐡𝐞 𝐔𝐒 𝐆𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭. A heartfelt gratitude to Shilpa Reddy, Sudarshan Jain and Vikas Dandekar, for organizing and moderating this insightful round table! Telangana Lifesciences Indian Pharmaceutical Alliance CII Southern Region #pharmaceutical #biotech #ceoroundtable

Our Safety Health Environment & Sustainability (SHE & S) team concluded its observance of #WorldEnvironmentMonth this week across our manufacturing sites on a high note. In line with this year's theme around land restoration, stopping desertification and building drought resilience, we conducted 58 site walks for water management and 10 for energy conservation. 68 ambassadors conducted trainings on water and energy respectively. 894 colleagues enthusiastically participated in quizzes themed around water & environment compliance and energy last week. They also built a communication toolbox on energy conservation. Our Waste Management Ambassadors also addressed 160 students from Raghu College of Pharmacy, Pydibheemavarm. In collaboration with the Confederation of Indian Industry (CII), we also conducted a webinar on Energy and Climate change. Our manufacturing team in Bachupally, Hyderabad distributed over 75 native plant species across our plant site. Our efforts in environmental stewardship continue beyond a single observance day or month, as an organisation and as individuals! #WeAreDrReddys #DrReddysXSustainability #ESG #GoodHealthCantWait #SDG7 #SDG13

Today we took a significant step towards building our consumer healthcare business globally!   We have signed an agreement to acquire the global brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States from Haleon plc. The portfolio falls in the Nicotine Replacement Therapy (NRT) category. The portfolio to be acquired has an extensive footprint in over 30 countries globally, spanning Europe, Asia, Australia, Canada, and Latin America. Nicotinell is the second biggest brand globally (excluding the United States) in the NRT category, ranks among the top 15 biggest brands among all OTC brands in Europe (excluding Russia, Italy), and ranks 32 among all OTC global brands (excluding the U.S.). NRT is recommended by the ‘World Health Organization Model List of Essential Medicines’ for nicotine use disorders. NRT also played a key role in the WHO’s ‘Access Initiative for Quitting Tobacco’ launched in 2020 to help tobacco users quit to reduce the risk of severe outcomes from COVID-19 infection.   We continue to focus on our core business of generics, branded generics, API, OTC, and biosimilars. Alongside this, we have been investing in growth drivers of the future in three areas – access to novel molecules (NCEs, NBEs, CAR-T); digital therapeutics (wearables, apps); and consumer healthcare (including nutrition and OTC wellness products). Under consumer healthcare, in recent years, we have increased our presence in nutrition and OTC wellness in markets around the world including the U.S., UK, Emerging Markets and India, including a recent joint venture with Nestlé India. The acquisition of this global portfolio of consumer healthcare products led by the global brand Nicotinell is a logical extension of these efforts. Given the strong and steady performance of this portfolio over the years and its global advantages, it is the ideal anchor around which to build a larger global OTC platform. For more details, please visit: https://bit.ly/4cCJiiK #WeAreDrReddys #GoodHealthCantWait